Making the
Impossible
Possible.Possible.
Therapeutics
Platform technologies capable of creating first- and best-in-class medicines for human diseases with high unmet need.
BioTools and Diagnostics
Approaches that create novel capabilities to see biological processes in a new light.
Synthetic Biology
Pushing the boundaries of what biology can do, changing the ways we heal, consume, and live.
Ensocell is identifies cells that drive and maintain disease in several inflammation and immunology conditions using a proprietary data and AI platform. They are creating first-in-class medicines against targets on these disease-driving cells.
Sector:
Therapeutics
Status:
Active
Mythic has uncovered a key mechanism governing how antibody drugs interact with target cells. Using this understanding, Mythic is significantly improving upon existing FDA-approved antibody therapies for oncology, both in terms of safety and efficacy.
Sector:
Therapeutics
Status:
Active
Freya is revolutionizing women's health through restoration of healthy vaginal microbiomes. Freya's first centers around improving the efficacy of in-vitro fertilization.
Sector:
Therapeutics
Status:
Active
Bolstered by FDA’s breakthrough therapy designation, Compass is developing patent-protected psilocybin formulations for the treatment of intractable mood disorders.
Sector:
Therapeutics
Status:
Exited
Delix is developing a class of novel non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles for the treatment of psychiatric and neurological indications.
Sector:
Therapeutics
Status:
Active
Finch is developing full spectrum and rationally selected microbiome-based drugs for the treatment of recurrent Clostridium Difficile infections, Autism Spectrum Disorder, Hepatitis B, Ulcerative Colitis, Crohn's disease, and several more.
Sector:
Therapeutics
Status:
Exited
Replay is creating a novel, ambitious toolkit to deliver large DNA payloads efficiently to any cell type, addressing a rapidly growing cell and gene therapy market. Their platform includes a high-capacity HSV vector for gene delivery and a best-in-class hypoimmunogenic iPSC therapeutic platform.
Sector:
Therapeutics
Status:
Active
Stipple Bio intends to unlock cellular profiling and target discovery with epitope resolution. The company uses epitope-level resolution technology to enable single-cell profiling and target discovery, enabling users with therapies for a wide range of solid and hematologic malignancies.
Sector:
Therapeutics
Status:
Active
ReAx is developing a next-generation chemoproteomics platform which leverages chemical and biological insights to identify and target novel hotspots across the proteome in disease-relevant contexts.
Sector:
Therapeutics
Status:
Active
Tessera is developing large scale "Gene Writing" therapies for repairing deleterious human gene mutations via novel transposon and retrotransposon-based approaches.
Sector:
Therapeutics
Status:
Active
Type6 is developing a new class of bifunctional kinase inhibitors to drug a range of historically hard-to-target cancers. Their rational engineering approach creates highly specific, high avidity molecules.
Syndex Bio is a biotechnology company founded in 2022, specializing in the development of genomics-based tools for biological discovery. The company integrates molecular technologies, instrumentation, and artificial intelligence to accelerate the understanding, diagnosis, and treatment of diseases.
Sector:
BioTools & Diagnostics
Status:
Active
VedaBio is revolutionizing molecular biology with its breakthrough platform for near-instant molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. The CRISPR Cascade™ platform is poised to emerge as a new gold standard tool to empower decision-making across multiple industries.
Sector:
BioTools & Diagnostics
Status:
Active
Matterworks is building a machine-learning software platform to enable users of mass spectrometry (MS) instruments to avoid chromatography steps in analyzing metabolomics samples, thereby achieving faster MS performance and covering a significantly broader range of analytes per run.
Sector:
BioTools & Diagnostics
Status:
Active
Cellsonics is developing a proprietary SimpleFlow™ technology to enable the first fully automated tissue dissociation workflow from solid tissue to single cells while maintaining native gene expression.
Sector:
BioTools & Diagnostics
Status:
Active
General Inception is an institutional co-founder for science-based companies bringing specialized expertise, operational resources and capital to innovation.
Sector:
BioTools & Diagnostics
Status:
Active
Glyphic Biotechnologies is building a next-generation proteomics platform with the depth of a single amino acid sequence and breadth to achieve this over thousand to million heterogeneous peptides. Furthermore, their platform is the only platform that combines both depth and breadth to detect post-translational modifications.
Sector:
BioTools & Diagnostics
Status:
Active
Lightcast is developing a droplet-based instrument for highly multiplexed research workflows. Lightcast’s platform uses light patterns to precisely move the droplets (containing cells, antibodies, etc.) across all of their arrays, allowing for high throughput combinatorial reactions in a programed workflow.
Sector:
BioTools & Diagnostics
Status:
Active
Tasso is manufacturing a device for simple, painless at-home blood draws that can support multiple use cases in health, telemedicine (at-home-monitoring), and research (clinical trials).
Sector:
BioTools & Diagnostics
Status:
Active
Constructive Bio is pioneering approaches for building entirely synthetic genomes & for reprogramming the genetic code of living organisms for programmable polymer synthesis. Constructive Bio platform technologies have created virus resistant organisms, and are turning living cells into sustainable bio factories to realize the sustainable materials and therapies of the future.
Sector:
Synthetic Bio
Status:
Active
Aperiam Bio uses computational methods to stabilize recombinant protein structures, solving a ubiquitous problem in industrial biotechnology. Using their computational approach, Aperiam Bio can produce enzymes with enhanced activity, shelf stability, and an expanded range of compatible reaction conditions, enabling a broad range of protein-based products.
Sector:
Synthetic Bio
Status:
Active
Sestina is marshalling a suite of synthetic biology tools to engineer the metabolism of yeast strains to enable the utilization of cheap feedstocks (cellulosic sugar, corn syrup) as food to produce high value chemicals and enzymes.
Sector:
Synthetic Bio
Status:
Exited
Inscripta is making biology engineerable with its advanced CRISPR-based platform that offers a fully automated workflow with massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta plans to revolutionize gene-writing, as Illumina has done in gene-reading.
Sector:
Synthetic Bio
Status:
Active
SyntheX has developed a yeast engineering approach that enables the discovery and design of peptide-based drugs with novel modes of action that block tough-to-drug protein-protein interactions (PPIs).
Sector:
Synthetic Bio
Status:
Active
TARA is pioneering predictive cardiac tissue models to enable faster, safer, and more reliable development of new medicines. TARA is focused on three critical areas including cardiac toxicology, precision cardiology, and heart failure drug discovery.
Sector:
Synthetic Bio
Status:
Exited
Select Legacy Investments
